Back to top

messenger-rna: Archive

Sundeep Ganoria

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.

PFEPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

SNYNegative Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change

Zacks Equity Research

Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.

GSKNegative Net Change PFEPositive Net Change MRKNegative Net Change MRNANegative Net Change

Zacks Equity Research

Can Moderna Keep the Beat Streak Alive This Earnings Season?

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

MRKNegative Net Change MRNANegative Net Change CTMXPositive Net Change ARGXNegative Net Change

Zacks Equity Research

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.

VRTXPositive Net Change MRNANegative Net Change ANIPNegative Net Change ETNBNo Net Change